Biltekin Ezgi, Kahraman Nermin, Gul Ogun Ali, Akay Yasemin M, Akay Metin, Ozpolat Bulent
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Department of Biomedical Engineering, University of Houston, Houston, TX 77004, USA.
Int J Mol Sci. 2025 Jul 15;26(14):6792. doi: 10.3390/ijms26146792.
Glioblastoma multiforme (GBM) is an aggressive and molecularly heterogeneous brain cancer with a poor prognosis. Despite advancements in standard-of-care therapies, including surgery, radiotherapy, and temozolomide (TMZ), the median survival remains approximately 15 months, with a 5-year survival rate of less than 10%. We and others have demonstrated that FOXM1 is a critical oncogenic driver of GBM cell proliferation. However, the role of FOXM1 and its interaction with other oncogenic signaling pathways in GBM remains incompletely understood. In this study, we identified FOXM1, AXL, and eEF2K as highly upregulated oncogenes in GBM patient tumors. We demonstrated, for the first time, that FOXM1 directly interacts with AXL and eEF2K, regulating their expression and promoting GBM cell proliferation, migration, and invasion. Knockdown of these genes disrupted cell proliferation, spheroid formation, migration, and invasion, and induced apoptosis and ferroptosis. Additionally, inhibiting the FOXM1-AXL/eEF2K signaling axis sensitized GBM cells to TMZ, further enhancing apoptotic and ferroptotic responses. These findings highlight the critical role of the FOXM1-AXL/eEF2K signaling pathway in GBM progression and suggest that targeting this axis may offer a novel multitargeted therapeutic strategy in GBM.
多形性胶质母细胞瘤(GBM)是一种侵袭性强且分子异质性高的脑癌,预后较差。尽管在包括手术、放疗和替莫唑胺(TMZ)在内的标准治疗方法上取得了进展,但中位生存期仍约为15个月,5年生存率低于10%。我们和其他人已经证明,FOXM1是GBM细胞增殖的关键致癌驱动因素。然而,FOXM1在GBM中的作用及其与其他致癌信号通路的相互作用仍未完全了解。在本研究中,我们确定FOXM1、AXL和eEF2K是GBM患者肿瘤中高度上调的致癌基因。我们首次证明,FOXM1直接与AXL和eEF2K相互作用,调节它们的表达并促进GBM细胞的增殖、迁移和侵袭。敲低这些基因会破坏细胞增殖、球体形成、迁移和侵袭,并诱导细胞凋亡和铁死亡。此外,抑制FOXM1-AXL/eEF2K信号轴会使GBM细胞对TMZ敏感,进一步增强凋亡和铁死亡反应。这些发现突出了FOXM1-AXL/eEF2K信号通路在GBM进展中的关键作用,并表明靶向该轴可能为GBM提供一种新的多靶点治疗策略。